Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for GVHD Prophylaxis in Pediatric Sickle Cell Disease
NCT02867800Phase 1Completed
- Start
- Jul 2016
- Primary completion
- Dec 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abatacept in graft-versus-host disease (GVHD). Primary endpoint: Number of patients who tolerate abatacept at 100 days. Started Jul 2016; status: completed.
02
Drugs
abatacept
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02867800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867800.